|Awarded On||February 16, 2022|
|Title||Enhancing the effects of peptide-receptor radionuclide therapy with a tumor- targeted radiosensitizer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Ali Azhdarinia|
|Cancer Sites||Pancreas, Small Intestine|
Nuclear medicine is a clinical specialty that involves delivering radioactive substances to tumors for imaging and therapy. The most well-developed approach for radionuclide therapy is for neuroendocrine tumors and is attributed to the robust expression of somatostatin receptors (SSTR) on the surface of these lesions. Peptides that target SSTR have be conjugated to cell-killing radioisotopes in a technique known as peptide-receptor radionuclide therapy (PRRT). Although PRRT is the most effective treatment for metastatic neuroendocrine tumors, objective response rates are less than 20%. Combining PRRT with a chemotherapy agent has shown improved antitumor effects through radiosensitization, b...